This company has been acquired
Surmodics (SRDX) Stock Overview
Provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SRDX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Surmodics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$42.98 |
| 52 Week High | US$43.00 |
| 52 Week Low | US$25.87 |
| Beta | 1.39 |
| 1 Month Change | 52.95% |
| 3 Month Change | 15.57% |
| 1 Year Change | 9.67% |
| 3 Year Change | 18.30% |
| 5 Year Change | 10.40% |
| Change since IPO | 957.97% |
Recent News & Updates
Recent updates
There's Reason For Concern Over Surmodics, Inc.'s (NASDAQ:SRDX) Massive 29% Price Jump
Jun 06
Is Now The Time To Look At Buying Surmodics, Inc. (NASDAQ:SRDX)?
May 30Surmodics (NASDAQ:SRDX) Is Experiencing Growth In Returns On Capital
May 02We Think Surmodics (NASDAQ:SRDX) Can Stay On Top Of Its Debt
Sep 17News Flash: Analysts Just Made A Notable Upgrade To Their Surmodics, Inc. (NASDAQ:SRDX) Forecasts
Jun 26An Intrinsic Calculation For Surmodics, Inc. (NASDAQ:SRDX) Suggests It's 27% Undervalued
Jun 22Is Surmodics (NASDAQ:SRDX) A Risky Investment?
May 14Market Participants Recognise Surmodics, Inc.'s (NASDAQ:SRDX) Revenues Pushing Shares 36% Higher
Apr 17Shareholders May Be Wary Of Increasing Surmodics, Inc.'s (NASDAQ:SRDX) CEO Compensation Package
Feb 03Surmodics (NASDAQ:SRDX) Has Debt But No Earnings; Should You Worry?
Jan 08Surmodics gets additional $125M in credit facility
Oct 17Shareholder Returns
| SRDX | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 3.8% | 3.4% | 1.9% |
| 1Y | 9.7% | 5.2% | 19.5% |
Return vs Industry: SRDX exceeded the US Medical Equipment industry which returned 1.2% over the past year.
Return vs Market: SRDX underperformed the US Market which returned 11.2% over the past year.
Price Volatility
| SRDX volatility | |
|---|---|
| SRDX Average Weekly Movement | 14.6% |
| Medical Equipment Industry Average Movement | 9.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SRDX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: SRDX's weekly volatility has increased from 9% to 15% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1979 | 389 | Gary Maharaj | www.surmodics.com |
Surmodics, Inc., together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD). The Medical Device segment engages in the provision of surface modification coating technologies to enhance access, deliverability, and predictable deployment of medical devices; and drug-delivery coating technologies to provide site-specific drug-delivery from the surface of a medical device for neurovascular, peripheral, coronary, and structural heart, and other markets, as well as manufacturing of vascular intervention medical devices, including drug-coated balloons, mechanical thrombectomy devices, and radial access balloon catheters and guide sheaths.
Surmodics, Inc. Fundamentals Summary
| SRDX fundamental statistics | |
|---|---|
| Market cap | US$614.51m |
| Earnings (TTM) | -US$17.63m |
| Revenue (TTM) | US$120.80m |
Is SRDX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SRDX income statement (TTM) | |
|---|---|
| Revenue | US$120.80m |
| Cost of Revenue | US$28.73m |
| Gross Profit | US$92.07m |
| Other Expenses | US$109.70m |
| Earnings | -US$17.63m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.23 |
| Gross Margin | 76.22% |
| Net Profit Margin | -14.59% |
| Debt/Equity Ratio | 26.7% |
How did SRDX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/11/20 13:24 |
| End of Day Share Price | 2025/11/18 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Surmodics, Inc. is covered by 8 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | Argus Research Company |
| Michael Petusky | Barrington Research Associates, Inc. |
| Jan Wald | Benchmark Company |